William McCorkindale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
William McCorkindale has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alpha Albert Lee
Department of Physics, University of Cambridge, Cambridge, UK
1 shared publication - Emma King-Smith
University of Cambridge
1 shared publication - Mihajlo Filep
Weizmann Institute of Science
1 shared publication - Nir London
Weizmann Institute of Science
1 shared publication
Latest Publications
- Open Access
- 9 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Deconvoluting Low Yield from Weak Potency in Direct-to-Biology Workflows with Machine Learning
High throughput and rapid biological evaluation of small molecules is an essential factor in drug discovery and development. Direct-to-Biology (D2B), whereby compound purification is foregone, has emerged as a viable technique in time efficient screening, specifically for PROTAC design and biological evaluation. However, one notable limitation is the prerequisite of high yielding reactions to ensure the desired compound is indeed the compound responsible for biological activity. Herein, we report a machine learning based yield-assay deconfounder capable of deconvoluting low yield from low potency to identify false negatives. We validated this approach by identifying promising SARS-CoV-2 main protease inhibitors with nanomolar activity that rivaled potency observed from the standard D2B workflow. Furthermore, we show how our framework can be utilized in a broad, in silico screen with to produce compounds of similar potency as a D2B assay.
- 9 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDeconvoluting Low Yield from Weak Potency in Direct-to-Biology Workflows with Machine Learning
High throughput and rapid biological evaluation of small molecules is an essential factor in drug discovery and development. Direct-to-Biology (D2B), whereby compound purification is foregone, has emerged as a viable technique in time efficient screening, specifically for PROTAC design and biological evaluation. However, one notable limitation is the prerequisite of high yielding reactions to ensure the desired compound is indeed the compound responsible for biological activity. Herein, we report a machine learning based yield-assay deconfounder capable of deconvoluting low yield from low potency to identify false negatives. We validated this approach by identifying promising SARS-CoV-2 main protease inhibitors with nanomolar activity that rivaled potency observed from the standard D2B workflow. Furthermore, we show how our framework can be utilized in a broad, in silico screen with to produce compounds of similar potency as a D2B assay.